None listed
Conditions
Brief summary
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in New Zealand. It affects people over the age of 45, and its prevalence increases sharply with age. AMD can significantly reduce people's quality of life from falls, hip fractures, depression, and increased living costs related to nursery care. One study predicted a 13% increase in the prevalence of AMD in NZ from 2014 to 2026, due to our ageing population. AMD requires frequent screening for early diagnosis, which creates an ever-increasing burden on patients and DHBs. This could potentially be reduced through home vision monitoring. The most frequent complaint from AMD patients is reading. Conventional visual acuity testing is not effective at monitoring the disease progression. We aim to develop a program for everyday devices, such as the iPad, to utilise novel eye-tracking technology to monitor reading patterns and detect early changes in AMD during a patient’s daily reading time.
Interventions
Group 1: intermediate age-related macular degeneration (iAMD) subjects; Group 2: neovascular age-related macular degeneration (nAMD) subjects.
Each session takes approximately 40 minutes and includes the measurement of visual acuity, contrast sensitivity, optical coherent tomography (OCT), MNReading test, fixation eye-tracking task and reading eye-tracking task. Each subject receives three sessions three months apart.
A reading App on Apple iPad to track eye movement parameters. Subjects are r
Group 1: intermediate age-related macular degeneration (iAMD) subjects; Group 2: neovascular age-related macular degeneration (nAMD) subjects. Each session takes approximately 40 minutes and includes the measurement of visual acuity, contrast sensitivity, optical coherent tomography (OCT), MNReading test, fixation eye-tracking task and reading eye-tracking task. Each subject receives three sessions three months apart. A reading App on Apple iPad to track eye movement parameters. Subjects are required to read some general reading passages. The reading app is specifically designed for this study. The location is at Tony Han Optometrists Ltd, Tauranga, New Zealand. Only the primary investigator, Tony Han, will administer the tests.
Sponsors
University of Auckland
Study design
Allocation
Non-randomised trial
Intervention model
Parallel
Primary purpose
Diagnosis
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
• Age 50 years and over • Clear ocular media • No retinal comorbidities, such as glaucoma or any other macular diseases. • Not taking any retinotoxic drugs • Pass cognition test • Group One: at least one eye has intermediate AMD; Group Two: at least one eye has neovascular AMD; Group Three: both eyes are normal.
Exclusion criteria
• Amblyopia • Ocular media opacity • No retinal comorbidities, such as glaucoma or any other macular diseases. • Taking retinotoxic drugs • Fail cognition test • Unable to sign consent form • Unable to understand English • Unable to home test
Outcome results
None listed